A Phase I Study to Assess the Safety, Tolerability and Biomarker Profiles of CBA-1535, Recombinant Protein Tribody in Patients With Previously Treated Advanced Solid Tumors
Latest Information Update: 19 Jun 2025
At a glance
- Drugs CBA 1535 (Primary) ; Pembrolizumab
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Chiome Bioscience
Most Recent Events
- 19 Jun 2025 New trial record